Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Flaherty

Showing results (151-160 of 204) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|October 1, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|January 11, 2024
Deep Learning Classification of Usual Interstitial Pneumonia Predicts OutcomesStephen M Humphries, Devlin Thieke, David Baraghoshi, et al.
The New England Journal of Medicine|March 11, 2026
Inhaled Treprostinil for Idiopathic Pulmonary FibrosisSteven D Nathan, Peter Smith, Chunqin Deng, et al.
The Lancet. Respiratory Medicine|April 11, 2014
Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trialGanesh Raghu, David Lynch, J David Godwin, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 9, 2012
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosisPayal K Naik, Paul D Bozyk, J Kelley Bentley, et al.
Annals of the American Thoracic Society|July 25, 2022
The Association between Exposures and Disease Characteristics in Familial Pulmonary FibrosisCarla R Copeland, Edwin F Donnelly, Mitra Mehrad, et al.
ERJ Open Research|June 24, 2021
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung diseaseRobin Deterding, Matthias Griese, Gail Deutsch, et al.
Annals of the American Thoracic Society|October 24, 2017
Reply: Improving Care for Patients with Interstitial Lung Disease, Using Machine Learning, Requires Transparency and ReproducibilityGiulia C Kennedy, Neil M Barth, P Sean Walsh, et al.
The European Respiratory Journal|December 14, 2022
Progressive pulmonary fibrosis: an expert group consensus statementSujeet K Rajan, Vincent Cottin, Raja Dhar, et al.
BMC Genomics|December 19, 2024
Computational deconvolution of cell type-specific gene expression in COPD and IPF lungs reveals disease severity associationsMin Hyung Ryu, Jeong H Yun, Kangjin Kim, et al.
Pageof 21

Showing results (151-160 of 204) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|October 1, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|January 11, 2024
Deep Learning Classification of Usual Interstitial Pneumonia Predicts OutcomesStephen M Humphries, Devlin Thieke, David Baraghoshi, et al.
The New England Journal of Medicine|March 11, 2026
Inhaled Treprostinil for Idiopathic Pulmonary FibrosisSteven D Nathan, Peter Smith, Chunqin Deng, et al.
The Lancet. Respiratory Medicine|April 11, 2014
Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trialGanesh Raghu, David Lynch, J David Godwin, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 9, 2012
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosisPayal K Naik, Paul D Bozyk, J Kelley Bentley, et al.
Annals of the American Thoracic Society|July 25, 2022
The Association between Exposures and Disease Characteristics in Familial Pulmonary FibrosisCarla R Copeland, Edwin F Donnelly, Mitra Mehrad, et al.
ERJ Open Research|June 24, 2021
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung diseaseRobin Deterding, Matthias Griese, Gail Deutsch, et al.
Annals of the American Thoracic Society|October 24, 2017
Reply: Improving Care for Patients with Interstitial Lung Disease, Using Machine Learning, Requires Transparency and ReproducibilityGiulia C Kennedy, Neil M Barth, P Sean Walsh, et al.
The European Respiratory Journal|December 14, 2022
Progressive pulmonary fibrosis: an expert group consensus statementSujeet K Rajan, Vincent Cottin, Raja Dhar, et al.
BMC Genomics|December 19, 2024
Computational deconvolution of cell type-specific gene expression in COPD and IPF lungs reveals disease severity associationsMin Hyung Ryu, Jeong H Yun, Kangjin Kim, et al.
Pageof 21